A Phase 2 interventional study of Maraviroc and Mannitol in Ischemic Stroke, Stroke and Stroke Acute, sponsored by Emmanuel Carrera. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Emmanuel Carrera · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Ischemic Stroke with a site in Switzerland — 27 open to participants now, 33 under way, 3 of them phase 3. Ischemic Stroke · Switzerland.
Among the 86 studies in Ischemic Stroke with a site in Switzerland, this one is the 34th largest by planned enrollment of the 42 interventional ones that give a count, is one of 10 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 23 of the 32 other live ones, and was the 82nd registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →27 of the 86 studies in Ischemic Stroke with a site in Switzerland are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Switzerland, Belgium, Germany and 3 more countries
Ages 18+
Sigmund Freud PrivatUniversitat · Sites in Switzerland, Austria, Germany
Ages 18+
Insel Gruppe AG, University Hospital Bern · Sites in Switzerland
Ages 18+
Penumbra Inc. · Sites in Switzerland, Australia, Canada and 2 more countries
Ages 18–80
University of Zurich · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is below the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.
Median enrollment 487 across the 42 interventional studies, 481 across the 44 observational. Of the 45 that completed or were terminated, 14 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 86 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Emmanuel Carrera as lead sponsor.
Emmanuel Carrera has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
10 of the studies in Ischemic Stroke with a site in Switzerland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06394180University Hospital, Basel, SwitzerlandPeRforation EVents During ENdovascular Therapy for Acute Ischemic Stroke | 2026-12 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04862507Universitätsklinikum Hamburg-EppendorfImproving Low ASPECTS Stroke Thrombectomy | 2027-01-01 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
| NCT04075084Biotronik SE & Co. KGObservation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs) | 2027-05-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 86 studies in Ischemic Stroke with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
Stroke is a common disease and one of the leading causes of death and disability worldwide. Despite advances in acute stroke therapies (intravenous thrombolysis and/or mechanical thrombectomy), deficits remain frequent after stroke. Pharmacological approaches have the benefit of being independent of patient participation, are easily administered, and involve limited medical resources. Unfortunately, the efficacy of several drugs that improve behavioural in preclinical models have yet to be confirmed in humans. Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist has shown promise in preclinical models, and instead of targeting neurotransmitters, is believed to augment rehabilitation by decreasing infarct size, increasing neuroplasticity, and most importantly, improving behaviour.
The MASTER trial is a single-center, double-blinded, randomized placebo-controlled, phase II clinical trial designed to evaluate the efficacy of Maraviroc (Celsentri) compared to a placebo, in improving outcomes following ischemic stroke in the early stage of recovery. 80 patients will be recruited within 5 days of stroke onset, and will receive either Maraviroc or a placebo drug for 90 days.
Participants will be assessed using a combination of clinical measurements, motor tests, and biometrics throughout the 90 days of intervention, and upon follow-up at 6-months post stroke onset. Several types of brain images will be obtained before and after the intervention period (day 0 and day 90), and participants will also perform a motor learning task before and after the intervention period (day 0 and day 90). Study personnel and participants will be blinded to the treatment, which will be randomly assigned to an intervention group with stratification based on side of the infarct and motor deficit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Maraviroc (Celsentri) 300 mg twice daily
Drug: Maraviroc
Placebo (Mannitol) encapsulated
Drug: Mannitol
Maraviroc (300mg) twice daily for 90 days
Also known as: Celsentri
Placebo intervention
Upper Extremity Fugl-Meyer Assessment (FMA-UE) Score
Reliable and validated score of motor function of the upper extremities after stroke. Range: 0-66, higher values indicating better motor function.
Time frame: Day 90
Motor Learning Score
A motor sequence learning score assessing the capability of the participant to learn a finger tapping sequence of 6 items.
Time frame: Day 0, 90
Number of adverse events (AE) of special interest
The number of patients experiencing AE of special interest : MACE (Major Adverse Cardiovascular Events) - Acute myocardial infarction ; Acute coronary syndrome ; Stroke ; Heart failure ; All cause death ; Cardiovascular death ; Revascularization AND any liver adverse events AND any infection adverse events. Assesed by: CTCAE v5.0
Time frame: Day 0-180 (inclusive)
Number of Serious Adverse Events (SAE)
Number of any SAEs occuring during the study follow-up. Assessed by: CTCAE v5.0.
Time frame: 0-180 days (inclusive)
9-hole Peg Test (Time)
The 9-hole peg test is used to measure dexterity. It is measured in seconds to complete the task, with lower duration indicating better dexterity.
Time frame: Day 0, 30, 60, 90, and 180.
Pinch force
Pinch force will be measured using a finger dynamometer, measured in kg. A greater value indicates greater finger strength.
Time frame: Day 0, 30, 60, 90, and 180.
Grip strength
Grip strength will be measured using a hand dynamometer. Strength is measured in kg, with a greater value indicating stronger grip strength.
Time frame: Day 0, 30, 60, 90, and 180.
National Institute of Health Stroke Scale (NIHSS)
A 15-item neurologic examination stroke scale (0 - 42), with higher scores indicating greater neurological impairment.
Time frame: Day 0, 30, 60, 90, 180
Modified Rankin Scale (mRS)
An ordinal scale measuring degree of dependence and disability following stroke, ranging from 0 to 6. A lower score indicates greater independence and less disability. 6 indicates death.
Time frame: Day 0, 30, 60, 90, 180
Barthel Index
A scale measuring independence for activities of daily living, on a scale from 0 to 100. Higher scores indicate greater functional independence.
Time frame: Day 0, 30, 60, 90, 180
Functional brain connectivity
Correlated Blood Oxygen Level Dependent (BOLD) imaging responses in the brain derived from resting state functional MRI scanning (values from 0 to 1, greater values indicating more connectivity), focussing on core motor and peri-infarct functional connectivity.
Time frame: Day 0, 90
Structural brain connectivity
Diffusion weighted imaging (DWI) derived structural connectivity, measured as fractional anisotropy of connecting tracts (values of 0 to 1, higher values indicating more directed water diffusion) , focussing on core motor and peri-infarct connectivity.
Time frame: Day 0, 90
Neurite Density Index
Microstructure analysis of the brain derived from a multi-shell Diffusion Weighted Imaging (DWI) MRI sequence, using a neurite density index (0 - 1). Greater values indicate greater density of neurites.
Time frame: Day 0, 90
Brain metabolite concentrations
Measurement of brain metabolite concentrations - N-acetylaspartate (NAA), Glutamate-Glutamine complex (Glx), Gamma-aminobutyric Acid (GABA), Creatinin (Cr) - using whole-brain magnetic resonance spectroscopic imaging (MRSI).
Time frame: Day 0, 90
Plan to share: Yes — Anonymized patient data of the primary and secondary study outcomes (FMA-UE, global functioning scores, motor learning scores) are currently anticipated to be shared dependent on participant consent to data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: The IPD and supporting information will be available following the publication of the results (est. 2028) and will be available indefinitely.
Access criteria: IPD will be available in a de-identified format to ensure participant confidentiality. Access will be granted to qualified researchers upon reasonable request, subject to prior approval by the sponsor and the demonstration of approval from a competent ethics committee. The shared data will include de-identified IPD that underlies the results reported in the publication (text, tables, figures, and appendices). Supporting documents such as the study protocol, statistical analysis plan, and clinical study report may also be available. Data will be accessible through a secure platform or via direct request after publication of the main study results.
Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.
Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 29 months is close to that.
Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc